Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals Plc has completed the initial tranche of its US $250 million share repurchase program, having bought back 7,076,403 ordinary shares for £93.1 million at an average price of £13.15 per share, with all repurchased shares being cancelled. The company has also commenced the second tranche of the buyback program, managed by J.P. Morgan Securities plc, which will continue until no later than September 11, 2026, with an aggregate purchase price of up to US $125 million. Following these transactions, Hikma's total issued ordinary shares will be 214,810,050.

Disclaimer*

UK 100